OnDosis
Joshua Carney is currently serving as the Chief Digital Officer (CDO) at OnDosis, starting from March 2021. Prior to this role, they worked at Essity from November 2017 to February 2021, holding various positions such as Global IoT Services Manager, Global Head Embedded Systems (IoT) Connected Solutions, and IQ Solution Global Innovation Manager. Before joining Essity, they were employed at SCA - Hygiene and Forest Products Company as the Global Innovation Technical Manager, IoT Medical, Professional Care from April 2014 to June 2017. Joshua also served as the Global Innovation Technical Manager Adjacent Concepts Professional Care at SCA Hygiene from July 2012 to April 2014. Earlier in their career, they worked at SCA Personal Care as a Global Concept Innovation Engineer/Early Development Product Developer from September 2010 to July 2012, and as an R&D Product Development Engineer from November 2006 to September 2010. Joshua Carney started their professional journey as a Biomaterials R&D Engineer at Kensey Nash Corporation from January 2005 to November 2006. Their earliest experience in the field was as a Research and Design Assistant Engineer at Synthes from September 2000 to March 2001.
Joshua Carney attended Mainland Regional High School from 1994 to 1999. Joshua then went on to study Bio-Med Engineering with a focus on Bio-Mechanics at Drexel University School of Biomedical Engineering, Science and Health Systems from 1999 to 2004.
OnDosis
1 followers
OnDosis proprietary technology delivers flexible and individualized dosing of oral medicines formulated as micro units. They are focused on providing reassurance in disease management, supporting adherence and providing greater convenience for patients. OnDosis is currently developing products for individualized dosing in diseases with asignificant burden on patients and healthcare such as ADHD, pain management and immunosuppression for organ transplants. Hundreds of thousands of patients with these conditions could be helped by improved dosing, ultimately leading to improving health care outcomes.The flexibility of OnDosis technology provides the potential for application across several disease areas and patient segments where conventional tablets or capsules often does not provide a good fit for the patient or treatment goal.OnDosis was founded in 2017 and is headquartered in Gothenburg, Sweden, based on an idea that was spun-out from AstraZeneca, using technology based on development work initiated there. It was founded by GU Ventures and Martin Olovsson. OnDosis operates a network of strategic partners across all core functions including formulation and device development, IP, Regulatory and Business Development.